About UsProductsNewsClinical TrialCorporate RelationsResources


Zuragen™ Injection




Biofilm Antimicrobial Effectiveness:
S. aureus Biofilm Colonization Inhibition and Elimination

On October 25, 2008, Dr. Karin Sauer of The Research Foundation, The State University of New York at Binghamton, presented new research regarding the impact of the novel antimicrobial/antithrombotic Zuragen™ as measured against Heparin and saline in combating biofilm colonization. The study was done on 3-day old, steady state S. aureus biofilms. (Staphylococcus aureus has been associated with costly catheter-related bloodstream infections (CRBSI), and often colonizes as biofilms.)

Compared to untreated biofilms, treatment with Zuragen™ for 1 hour resulted in a 27-fold reduction in the biofilm biomass. After 48 hours, Zuragen™ resulted in a 240-fold reduction in the biofilm biomass. In contrast, treatment with Heparin for 1 and 24 h. only resulted in a ~2.4 fold and 1.5 fold reduction in biofilm biomass, respectively. For more information, view the newest research poster, Clinical Abstract (ICAAC / ASN 2008).